Most Read

The funding will facilitate the establishment of Nilo’s laboratories in New York City, the growth of the team, and the advancement of preclinical programmes. Furthermore, the company has appointed

The funds will be used to advance the late-stage clinical development of the company’s leading candidate, inhaled AERO-007. This nebulised LABA/LAMA combination is being developed as a potential

Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with

Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with

The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within

The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson’s disease. This programme

The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several

The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in